Joincare(SH:600380)2023-10-25 16:00Financial Performance - The company's revenue for Q3 2023 was approximately ¥3.93 billion, representing a decrease of 11.59% compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was approximately ¥268.21 million, down 17.55% year-on-year[4]. - The basic earnings per share for Q3 2023 was ¥0.1418, a decline of 18.87% compared to the same quarter last year[4]. - For the first nine months of 2023, the company achieved a net profit of approximately ¥1.08 billion, with a year-on-year decrease of about 3.81%[6]. - Total operating revenue for the first three quarters of 2023 was CNY 12,651,257,386.44, a decrease of 2.77% compared to CNY 13,011,966,738.16 in the same period of 2022[18]. - Net profit attributable to shareholders of the parent company for Q3 2023 was CNY 1,083,649,154.75, compared to CNY 1,126,561,953.23 in Q3 2022, a decline of 3.81%[19]. - The company reported a net profit of CNY 2,244,795,311.84 for the first three quarters of 2023, an increase from CNY 2,201,270,281.19 in the same period of 2022, representing a growth of 1.97%[18]. - Basic earnings per share for Q3 2023 were CNY 0.5682, down from CNY 0.5983 in Q3 2022[19]. Cash Flow and Investments - The company reported a cash flow from operating activities of approximately ¥2.46 billion for the first nine months, down 5.72% year-on-year[4]. - Total cash inflow from operating activities for the first three quarters of 2023 was CNY 14,272,677,392.03, a decrease of 1.3% compared to CNY 14,461,251,432.77 in the same period of 2022[20]. - Net cash flow from operating activities was CNY 2,459,851,744.70, down 5.7% from CNY 2,608,992,532.97 year-on-year[20]. - Cash inflow from investment activities totaled CNY 766,101,409.50, significantly up from CNY 353,541,213.26 in the previous year[20]. - Net cash flow from investment activities was -CNY 675,752,976.46, an improvement from -CNY 886,929,197.44 in the same period last year[20]. - Cash inflow from financing activities was CNY 3,385,226,952.90, down 46.5% from CNY 6,320,346,629.59 in 2022[21]. - Net cash flow from financing activities was -CNY 1,987,651,014.91, compared to a positive cash flow of CNY 873,841,344.96 in the same period last year[21]. - The company received CNY 390,344,459.46 from the recovery of investments, an increase from CNY 216,970,980.42 in the previous year[20]. - The company paid CNY 1,570,166,936.38 in dividends and interest, up from CNY 1,314,118,888.43 in the same period last year[21]. - The company reported a cash outflow of CNY 5,372,877,967.81 from financing activities, slightly down from CNY 5,446,505,284.63 in the previous year[21]. Assets and Liabilities - The total assets as of September 30, 2023, were approximately ¥35.77 billion, showing a slight increase of 0.11% from the end of the previous year[5]. - As of September 30, 2023, total current assets amounted to ¥23,239,240,796.98, slightly up from ¥23,177,507,036.65 at the end of 2022[16]. - Total assets reached ¥35,769,669,256.09, compared to ¥35,729,253,651.41 at the end of 2022[16]. - The company’s total liabilities were not specified but are part of the overall financial health assessment[16]. - The total liabilities as of Q3 2023 amounted to CNY 13,676,073,911.37, a slight decrease from CNY 13,709,025,953.74 in the previous year[17]. - The company's total equity reached CNY 22,093,595,344.72 in Q3 2023, compared to CNY 22,020,227,697.67 in Q3 2022, indicating a marginal increase[17]. Shareholder Information - Total number of common shareholders at the end of the reporting period was 79,393[13]. - The largest shareholder, Shenzhen Baiye Yuan Investment Co., Ltd., holds 895,653,653 shares, accounting for 46.83% of total shares[14]. - The company has a share repurchase account holding 46,513,711 shares, representing 2.43% of total shares[14]. Revenue Segments - The revenue from chemical preparations for the first nine months was approximately ¥6.57 billion, a decrease of 9.20% year-on-year[6]. - The company reported a significant increase in revenue from traditional Chinese medicine preparations, which grew by 49.48% year-on-year to approximately ¥1.29 billion[6]. Research and Development - Research and development expenses for the first three quarters of 2023 were CNY 1,211,596,866.40, slightly down from CNY 1,232,505,100.33 in 2022[18]. Other Comprehensive Income - Other comprehensive income after tax for Q3 2023 was CNY -22,658,520.87, compared to CNY 80,412,282.94 in Q3 2022, indicating a significant decline[19].